Navigation Links
Questcor Pharmaceuticals Issues Statement
Date:1/11/2012

ANAHEIM, Calif., Jan. 11, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) today announced it became aware that an investor blog is preparing to issue a report regarding the Company's marketing and business practices.  Questcor issued the following statement:

The Company believes that its marketing and business practices are consistent with regulatory requirements and industry standard practices.  Questcor markets H.P. Acthar® Gel for the treatment of acute exacerbations of multiple sclerosis (MS) in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age.  The Company maintains a compliance program, which is led by an experienced compliance officer and includes the active participation of Questcor's executive management team.  Questcor attributes its success to the ability of Acthar to potentially address the unmet medical need associated with MS exacerbations and nephrotic syndrome.  The Company is committed to providing access to Acthar to patients who need it, and marketing Acthar in accordance with regulatory requirements and industry standard practices.  Questcor plans to speak with the publication to discuss the Company and its marketing and business practices.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product, Acthar, helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, or SLE, for which Acthar is approved as both a maintenance therapy and to treat exacerbations.  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  In October 2011, Forbes magazine ranked Questcor number one in its annual rankings of America's Best Small Companies.  For more information, please visit www.questcor.com.

 

 


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Reports Solid Fourth Quarter Results
2. Questcor to Discuss Results From FDA Panel Meeting
3. Trading Halted Today in Questcor Pharmaceuticals Common Stock
4. Questcor to Present at the Jefferies 2010 Global Life Sciences Conference
5. Questcor Receives Notification of PDUFA Date Extension to September 11, 2010
6. Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors
7. Questcor to Present at UBS Global Life Sciences Conference
8. Questcor and Child Neurology Foundation Support the 2nd Annual Infantile Spasms (IS) Awareness Week
9. Questcor Teams With Child Neurology Foundation (CNF) to Fund Infantile Spasms Scientific Research
10. Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference
11. Questcor Reports Third Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... BOSTON , April 20, 2017   ZappRx, Inc ... the specialty drug prescribing process, today announced it closed $25 ... Fund, a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included ... A round in 2014, and GV (formerly Google ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, Chile, ... their offering. ... Latin American pharmaceutical contract manufacturing services market is anticipated to ... registration cost in Latin American countries and continuous economic growth ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... As part of the nationwide ... honor the victims of the Holocaust and Nazi persecution, Center for Medicine after ... Auschwitz on its CMATH Champions trip to Germany and Poland next week. , The ...
(Date:4/24/2017)... TX (PRWEB) , ... April 24, 2017 , ... The ... the glitterati, those unreal icons inhabiting the rarified air of pop and film stardom.(1) ... paparazzi and anyone snapping pictures: the smile. Grins now run the gamut from being ...
(Date:4/24/2017)... Calif. (PRWEB) , ... April 24, 2017 , ... The ... $1.6 million in charitable dental services to 1,961 people during the April 22-23 event ... at no charge to Californians who experience barriers to care, CDA Cares educates the ...
(Date:4/24/2017)... ... 24, 2017 , ... Veteran Theresa James awoke to the sound of her ... In “Healing Tears,” James depicts every parent’s worst nightmare, when her three children were ... conversations and situations throughout my divorce,” James said. “After the death of my children, ...
(Date:4/24/2017)... Boca Raton, Florida (PRWEB) , ... April 24, ... ... that develops a variety of unique liquid food supplements, announced its popular products ... of nutritional products. , ALP Nutrition® prioritizes the use of premium natural ...
Breaking Medicine News(10 mins):